Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06520-8034, USA.
Hum Reprod. 2010 Oct;25(10):2612-21. doi: 10.1093/humrep/deq210. Epub 2010 Aug 17.
Double-blind, randomized clinical trials are the preferred approach to demonstrating the effectiveness of one treatment against another. The comparison is, however, made on the average group effects. While patients and clinicians have always struggled to understand why patients respond differently to the same treatment, and while much hope has been held for the nascent field of predictive biomarkers (e.g. genetic markers), there is still much utility in exploring whether it is possible to estimate treatment efficacy based on demographic and baseline variables.
The pregnancy in polycystic ovary syndrome (PPCOS) study was a prospective, multi-center, randomized clinical trial comparing three ovulation induction regimens: clomiphene citrate (CC), metformin and the combination of the two. There were 446 women who ovulated in response to the treatments among the entire 626 participants. In this report, we focus on the 418 women who received CC (alone or combined with metformin) to determine if readily available baseline physical characteristics and/or easily obtainable baseline measures could be used to distinguish treatment effectiveness in stimulating ovulation. We used a recursive partitioning technique and developed a node-splitting rule to build decision tree models that reflected within-node and within-treatment responses.
Overall, the combination of CC plus metformin resulted in an increased incidence of ovulation compared with CC alone. This is particularly so in women with relatively larger left ovarian volumes (≥ 19.5 cubic cm), and a left ovarian volume <19.5 cubic cm was related to treatment outcomes for all subsequent nodes. Women who were older, who had higher baseline insulin, higher waist-to-hip circumference ratio or higher sex hormone-binding globulin levels had better ovulatory rates with CC alone than with the combination of CC plus metformin.
Polycystic ovary syndrome (PCOS) is a phenotypically diverse condition. Both baseline laboratory and clinical parameters can predict the ovulatory response in women with PCOS undergoing ovulation induction. Without a priori hypotheses with regard to any predictors, the observation regarding left ovary volume is novel and worthy of further investigation and validation.
双盲、随机临床试验是证明一种治疗方法优于另一种治疗方法的首选方法。然而,这种比较是基于平均的群体效应。虽然患者和临床医生一直在努力理解为什么患者对相同的治疗有不同的反应,并且尽管对新兴的预测生物标志物领域(例如遗传标志物)寄予厚望,但探索是否有可能根据人口统计学和基线变量来估计治疗效果仍然具有很大的意义。
多囊卵巢综合征(PPCOS)妊娠研究是一项前瞻性、多中心、随机临床试验,比较了三种促排卵方案:枸橼酸氯米酚(CC)、二甲双胍和两者的联合应用。在 626 名参与者中,有 446 名女性对治疗有排卵反应。在本报告中,我们重点关注接受 CC(单独或与二甲双胍联合使用)的 418 名女性,以确定是否可以使用现成的基线身体特征和/或易于获得的基线测量值来区分刺激排卵的治疗效果。我们使用递归分区技术和开发节点分裂规则来构建决策树模型,反映节点内和治疗内的反应。
总的来说,CC 联合二甲双胍比单独使用 CC 更能增加排卵的发生率。在左侧卵巢体积相对较大(≥ 19.5 立方厘米)的女性中尤其如此,而左侧卵巢体积<19.5 立方厘米与所有后续节点的治疗结果有关。年龄较大、基线胰岛素水平较高、腰臀比或性激素结合球蛋白水平较高的女性单独使用 CC 的排卵率优于 CC 联合二甲双胍。
多囊卵巢综合征(PCOS)是一种表型多样的疾病。基线实验室和临床参数都可以预测接受促排卵诱导的 PCOS 女性的排卵反应。在没有任何预测因子的先验假设的情况下,关于左侧卵巢体积的观察是新颖的,值得进一步研究和验证。